Abstract
Despite the remarkable efficacy of chimeric antigen receptor (CAR) T-cells in B-cell malignancies, their full potential in solid tumors has not yet been achieved. In a recent publication in Cell, Labanieh et al. developed a druggable CAR T-cell construct that allows optimal fine-tuning of CAR T-cells to achieve maximal efficacy and reduce toxicity.